BackBicycle Therapeutics Plc Overview
Bicycle Therapeutics Plc - ADR

Bicycle Therapeutics Plc Target Price

Analysts' average 12-month price target for Bicycle Therapeutics Plc is $12.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.98

Average Target Price

$12.00201.5% upside

1 analysts in the last 4 months

High: $12 | Low: $12

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-04-30JefferiesMaury Raycroft$12201.5% upsideOpen
2026-04-08Morgan Stanley$12201.5% upsideOpen
2026-03-17Truist FinancialGreg Renza$8101% upsideOpen
2026-03-17Morgan StanleyMaxwell Skor$13226.6% upsideOpen
2025-11-24Truist Financial$10151.3% upsideOpen
2025-10-31JMP SecuritiesReni Benjamin$12201.5% upsideOpen
2025-10-31RBC CapitalLeonid Timashev$11176.4% upsideOpen
2025-08-11RBC CapitalLeonid Timashev$27578.4% upsideOpen
2025-05-05Morgan StanleyMaxwell Skor$17327.1% upsideOpen
2024-12-18JMP SecuritiesReni Benjamin$26553.3% upsideOpen
2024-10-24OppenheimerJay Olson$481106% upsideOpen
2024-10-24B.Riley FinancialKalpit Patel$28603.5% upsideOpen
2024-09-16H.C. WainwrightSwayampakula Ramakanth$551281.9% upsideOpen
2021-10-07Roth CapitalAnthony Butler$651533.2% upsideOpen
2021-10-07Piper SandlerEdward Tenthoff$761809.5% upsideOpen

Bicycle Therapeutics Plc (BCYC) FAQ

Bicycle Therapeutics Plc's target price stands at $12. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $12 for BCYC implies 201.5% upside versus today's price ($3.98). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Bicycle Therapeutics Plc's target price evolved across reporting periods, while the comparison chart places BCYC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Bicycle Therapeutics Plc's reading of $12 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.